Biostatistics and Computational Biology Program The Biostatistics and Computational Biology Program carries out quantitative and computational research in a variety of areas relevant to understanding issues related to cancer. Program interests span a range of activities, from the technical development of quantitative or experimental methodologies to activities that emphasize substantive research programs in epidemiology, to biological research programs that use experimental approaches alongside computational methods. Program strengths include the development of rigorous statistical and mathematical methods for personalized medicine and molecular diagnostics, understanding the molecular biology of the adaptive immune response, and the development of approaches that address high impact opportunities in cancer research - including methods for the analysis of complex association studies and longitudinal data, and experimental/ computational methods that characterize variations in quantity, sequence, and structure of the human genome, transcriptome, and proteome. The program members also have leadership activities that impact cancer research at a national level, including a number of U01s, a variety of statistical coordinating centers -- the Southwest Oncology Group (SWOG), the National Wilms Tumor Study, the Women's Health Initiative (WHI), the Statistical Centers for the HIV/AIDS Research & Prevention (SCHARP), and the Early Detection Research Network (EDRN) - and the leadership of multiple widely adopted computing platforms. The goals of the program are (i) to develop rigorous statistical and mathematical methods relevant to predictive and personalized medicine; (ii) to develop and use experimental, technological, and companion computational or mathematical methods to gain understanding of the natural history of cancer; and (iii) to promote development, dissemination and use of statistical and computational methods in cancer research. The Biostatistics and Computational Biology Program has 42 members, 93% of whom have external funding or are new faculty members, across two institutions, three schools and seven departments. Members published a total of 813 papers in the previous grant period. Program members are highly collaborative and routinely work with epidemiological, clinical, and laboratory-based researchers in other programs to support the translation of our expertise across the CCSG - 54% of our manuscripts were inter-programmatic, 10% were intra- programmatic, and 19% inter-institutional . Our members have been successful in obtaining funding to support their research programs. Peer reviewed funding (direct) is $10.9M of which $5.4M is from NCI, and includes many single-investigator R01s, several U01s, a longstanding P01, a variety of other peer reviewed grants or fellowships, and large-scale collaborative working groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617732
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications